Pds Biotechnology CORP 8-K filings

PDS Biotechnology announced positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and immunocytokine PDS01ADC at the 2025 SITC Annual Meeting.

PDS Biotechnology Corporation requests an FDA meeting to explore an expedited approval pathway for PDS0101 in HPV16-positive Head and Neck Cancer, based on strong VERSATILE-002 trial data.

PDS Biotechnology announced a sub-analysis of its VERSATILE-002 trial showing PDS0101 significantly extended median overall survival in a difficult-to-treat head and neck cancer patient cohort.

PDS Biotechnology Corporation updated its corporate presentation, highlighting positive Phase 2 clinical trial results for PDS0101 in HPV16+ recurrent/metastatic HNSCC with a median overall survival of 39.3 months.

PDS Biotechnology announced final topline survival data from its VERSATILE-002 Phase 2 trial, showing a median overall survival of 39.3 months in HPV16-positive head and neck cancer patients.

PDS Biotechnology reported its second quarter 2025 financial results, showing an increased net loss but significant progress in its lead oncology clinical programs, including positive data from VERSATILE-002 and expansion of a colorectal cancer trial.

PDS Biotechnology Corporation announced that its PDS01ADC therapeutic, in combination with floxuridine, met pre-set criteria for expansion into Stage 2 of a Phase 2 clinical trial for metastatic colorectal cancer, led by the National Cancer Institute.

PDS Biotechnology Corporation has updated its corporate presentation, highlighting compelling Phase 2 clinical results for Versamune HPV in HPV16-positive recurrent/metastatic head and neck cancer and outlining plans for a pivotal Phase 3 trial.

PDS Biotechnology Corporation announced that its stockholders approved an amendment to its 2014 Equity Incentive Plan, increasing the share pool by over 3.1 million shares, and re-elected two Class A directors at its 2025 Annual Meeting.

PDS Biotechnology Corporation announced updated positive data from its VERSATILE-002 trial and other studies for Versamune HPV (PDS0101) in treating HPV16-positive head and neck cancers, presented at the 2025 ASCO Annual Meeting.

PDS Biotechnology announces positive extended follow-up data for VERSATILE-002 and additional trials evaluating Versamune HPV to be presented at the 2025 ASCO Annual Meeting.

PDS Biotechnology Corporation reported its Q1 2025 financial results, highlighted by the progress of the VERSATILE-003 Phase 3 clinical trial and upcoming presentations at ASCO.

PDS Biotechnology highlights promising preclinical results for its Infectimune-based universal flu vaccine at the IMMUNOLOGY2025 Annual Meeting, showcasing broad immune response against multiple influenza strains.

PDS Biotechnology Corporation enters into a securities purchase agreement for $20 million, issuing senior secured convertible debentures and warrants to strengthen its financial position.

Sir Richard Sykes will retire from the Board of Directors of PDS Biotechnology Corporation at the 2025 Annual Meeting of Stockholders.

PDS Biotechnology reports its full year 2024 financial results and provides an update on its clinical programs, highlighted by the initiation of a Phase 3 clinical trial for Versamune HPV in HPV16-positive head and neck cancer.

PDS Biotechnology announces FDA clearance of its IND application for a combination therapy targeting MUC1-positive metastatic colorectal cancer.

PDS Biotechnology initiates the VERSATILE-003 Phase 3 clinical trial to evaluate Versamune HPV in HPV16-positive head and neck cancer.

PDS Biotechnology Corporation has announced a registered direct offering to raise $11 million upfront, with the possibility of an additional $11 million upon full warrant exercise.

PDS Biotechnology announces the publication of positive clinical data in JAMA Oncology, showcasing promising survival and clinical responses in patients with recurrent/metastatic HPV-associated cancers treated with a triple combination therapy.

PDS Biotechnology announces positive circulating tumor DNA results for Versamune HPV, indicating potential as a broadly effective treatment for HPV16-associated cancers and plans for a Phase 3 trial in HPV16-positive HNSCC.

PDS Biotechnology reaffirms its plan to initiate the VERSATILE-003 Phase 3 clinical trial for Versamune HPV plus pembrolizumab in first-line treatment of recurrent and/or metastatic HPV16-positive head and neck squamous cell cancer (HNSCC) in Q1 2025.

PDS Biotechnology Corporation provided a business update, reported its third quarter 2024 financial results, and announced modifications to its Phase 3 trial design for its lead candidate, Versamune HPV.

PDS Biotechnology reports an 84.4% overall survival rate at 36 months for locally advanced cervical cancer patients treated with Versamune HPV and chemoradiation in a Phase 2 trial.

PDS Biotechnology Corporation is progressing its cancer immunotherapy programs, highlighted by positive Phase 2 results for Versamune HPV in head and neck cancer and the planned initiation of a Phase 3 trial.

PDS Biotechnology reported updated data from its VERSATILE-002 trial, showing promising results for its Versamune HPV treatment in combination with pembrolizumab for head and neck cancer.

PDS Biotechnology Corporation has amended its at-the-market offering agreement to allow for the potential sale of up to $50 million in common stock.

PDS Biotechnology reports alignment with the FDA on a Phase 3 trial design for their lead candidate and announces second quarter 2024 financial results with reduced operating expenses.

PDS Biotechnology will present updated Phase 2 clinical trial data for its Versamune HPV treatment in combination with chemoradiation for locally advanced cervical cancer at the 2024 ASTRO Annual Meeting.

PDS Biotechnology Corporation will release its second quarter 2024 financial results and provide a business update on August 13, 2024, before the market opens.